CTIX News 3.0200 10/01/2014 04:39:55 Cellceutix Corp (CTIX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cellceutix Corp (CTIX) 3.0200 $CTIX

Super Stock Profits OTC Daily Trading News: Cellceutix Corp, Virtus Oil and Gas Corp, Solar 3D, Inc. Alkame Holdings, Inc.
PR Newswire - Tue Sep 30, 8:32AM CDT
Cellceutix Corp (OTC: CTIX) continued is positive run regardless of the market downturn having hit yet another new 52 week high ahead of today's market action on the OTC. Cellceutix closed at $2.91 having registered the high of the day at $2.98. Traders will be looking for the stock which moved up to almost $5 million in volume on Monday to surpass $3.00 in today's session. For our latest commentary on Cellceutix as well as other up to date tock alerts please click here.

Cellceutix Provides Update to Shareholders
Marketwire - Wed Sep 24, 11:30AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications today has provided an update to its shareholders.

Cellceutix to President Obama: We Have the Tools and Will Rise Up to the Challenge to Prevent Antibiotic Resistant Bacteria Becoming a Serious Threat to Public Health
Marketwire - Fri Sep 19, 6:15AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, commends President Barack Obama for signing an Executive Order on Thursday, September 18, ordering federal agencies to launch a concerted effort to combat the growing threat from bacteria that is resistant to antibiotic treatment. The Obama administration's measures are part of the first major federal effort to confront a public health problem that takes at least 23,000 lives a year and has an estimated annual impact of on the national economy of $20 billion in excess direct health care costs.

Cellceutix Provides Initial Observations of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application to FDA for Phase 2 Trial of Brilacidin-OM for Oral Mucositis
Marketwire - Tue Sep 09, 2:00PM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce this update on its recently completed Phase 2b study of Brilacidin for the treatment of Acute Bacterial Skin and Skin Structure Infections ("ABSSSI" .

Cellceutix to Present at Rodman & Renshaw's 16th Annual Global Investment Conference
Marketwire - Fri Sep 05, 10:17AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announced today that Leo Ehrlich, CEO will be presenting Cellceutix at the 16th Annual Rodman & Renshaw Global Investment Conference, on Tuesday, September 9 at 3:20 PM EDT.

Cellceutix Appoints Dr. Barry Schechter to Board of Directors as Company Focuses on Meeting Requirements for Stock Exchange Uplisting
Marketwire - Tue Sep 02, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the appointment of Dr. Barry Schechter M.D. F.A.A.O. to the Cellceutix Board of Directors, effective October 1st, 2014. Dr. Schechter, a Principal and the Director of the Department of Cornea and External Disease at Florida Eye Microsurgical Institute, brings years of experience to Cellceutix through his specialization in ocular pathology and diseases, including infections.

Cellceutix Completes Enrollment in Phase 2b Clinical Trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
Marketwire - Tue Aug 19, 7:31AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, has announced the completion of enrollment in its Phase 2b trial comparing Brilacidin(TM) to daptomycin (Cubicin(R)) in patients with acute bacterial skin and skin structure infections (ABSSSI). Overall, 215 patients were randomized to one of three dosing regimens of Brilacidin (single dose 0.6mg/kg; single-dose 0.8mg/kg; 1.2mg/kg over 3 days) or 7 days of once daily daptomycin.

Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis
Marketwire - Mon Aug 11, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that the Company has just received the final toxicology report for Brilacidin-OM. Cellceutix is developing Brilacidin-OM as a new treatment for oral mucositis, a common and often debilitating inflammation and ulceration that occurs in the mouth as a side effect of certain cancer treatments, including chemotherapy and radiation therapy.

Cellceutix Anti-Psoriasis Drug Prurisol Meets Primary Endpoint of Clinical Trial
Marketwire - Fri Aug 08, 5:03AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that it has just received notice that the data from its Phase 1 trial of the Company's anti-psoriasis drug candidate Prurisol(TM) for the conversion of Prurisol to abacavir indicated "the areas are within passing Bioequivalency limits." Cellceutix believes it has met the primary endpoints and objectives of the study. Cellceutix is developing Prurisol(TM) under guidance from the U.S. Food and Drug Administration that a 505(b)(2) designation is an acceptable pathway to expedite development of the compound for treating psoriasis.

Cellceutix Believes Brilacidin on Track to Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment in Phase 2b Trial for Acute Bacterial Skin and Skin Structure Infections Expected This Month
Marketwire - Mon Aug 04, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to inform shareholders that it expects completion of enrollment in its Phase 2b trial of Brilacidin(TM) for Acute Bacterial Skin and Skin Structure Infections ("ABSSSI" , by the end of this month. Brilacidin is Cellceutix's lead antibiotic drug candidate in a new class of compounds called defensin-mimetics. Brilacidin is designed to act as a synthetic version of the naturally occurring defensins, peptides with antimicrobial activities that have been part of the innate immune response throughout evolution. By disrupting the structural integrity of bacteria, as opposed to interfering via a biochemical approach as most classes of antibiotics do, Brilacidin has an intrinsic ability to avoid the development of resistance.

Plague - Pipeline Review, H1 2014
M2 - Wed Jul 30, 2:42AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xgdb3j/plague_pipeline) has announced the addition of the "Plague - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Plague, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Plague and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Plague - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Plague and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Plague products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Mentioned: - Takeda Pharmaceutical - Summit Corporation - Mucosis - iBio - Cellceutix Corporation For more information visit http://www.researchandmarkets.com/research/xg...e_pipeline

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:23AM CDT
Research and Markets (http://www.researchandmarkets.com/research/g486rc/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Dainippon Sumitomo Pharma Co., Ltd. - Immtech Pharmaceuticals, Inc. - Cellceutix Corporation - Lytix Biopharma AS - PharmaIN Corporation - ImmuVen, Inc. - Arsanis Biosciences GmbH For more information visit http://www.researchandmarkets.com/research/g4...llinsuscep

Cellceutix Announces Breakthrough in the Formulation of Its Novel Antibiotic Brilacidin(TM), Plans Studies to Treat Diabetic Foot Ulcers
Marketwire - Mon Jul 14, 6:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a significant breakthrough has been made in the formulation of Brilacidin(TM), Cellceutix's lead antibiotic in its portfolio of novel compounds called defensin mimetics. Previously, Brilacidin was stored in a refrigerated state. Cellceutix has stabilized the formulation of Brilacidin so that it is now stable at room temperature. This positions the Company to move forward with the immediate development of Brilacidin for the treatment of infected diabetic foot ulcers. Ophthalmic and otitic formulations will soon follow for ophthalmic and otitis media indications.

Cellceutix Anti-Fungal Compounds Awarded $1.5 Million SBIR Grant
Marketwire - Mon Jun 23, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that a research collaboration with Fox Chase Chemical Diversity Center ("FCCDC" (http://www.fc-cdci.com) has led to the award of a Phase 2B Small Business Innovation Research (SBIR) grant to FCCDC from the National Institute of Allergy and Infectious Disease (NIAID) of the National Institute of Health (NIH).

Autism - Pipeline Review, H1 2014 - 20 Companies & 42 Drug Profiles
M2 - Fri Jun 20, 2:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ltzhjv/autism_pipeline) has announced the addition of the "Autism - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Autism, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Autism and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - F. Hoffmann-La Roche Ltd. - Dainippon Sumitomo Pharma Co., Ltd. - Novartis AG - Merz Pharma GmbH & Co. KgaA - Teva Pharmaceutical Industries Limited - Avanir Pharmaceuticals, Inc. - Snowdon Inc. - Curemark, LLC - Coronado Biosciences, Inc. - Omeros Corporation - Intra-Cellular Therapies, Inc. - Cellceutix Corporation - Heptares Therapeutics Ltd. - Otsuka Holdings Co., Ltd. - Reviva Pharmaceuticals Inc. - Naurex, Inc. - Nectid, Inc. - Mnemosyne Pharmaceuticals, Inc. - BioCrea GmbH - Saniona AB Drug Profiles - CM-AT - lurasidone hydrochloride - aripiprazole - cycloserine - fluoxetine - oxytocin - oxytocin - memantine hydrochloride - TSO - pioglitazone hydrochloride - oxytocin - oxytocin - (dextromethorphan hydrobromide quinidine sulfate) - oxytocin - oxytocin - RG-7314 - fluoxetine - fluoxetine - argipressin tannate - NU-211-01 NC-215-01 - Autologous Hematopoietic Stem Cells - glatiramer acetate - ITI-007 - Stem Cell Therapy for Central Nervous System Disorders - KM-391 - Program For Neurological Disorders - STX-110 - CN-2097 - acamprosate calcium - Small Molecules to Inhibit PI3K for Autism and Fragile X Syndrome For more information visit http://www.researchandmarkets.com/research/lt...m_pipeline

Cellceutix Clinical Trial of Anti-Cancer Drug Kevetrin Entering Eighth Cohort
Marketwire - Mon Jun 16, 6:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to report that the safety committee overseeing the Phase 1 clinical trial evaluating Cellceutix's lead anti-cancer drug Kevetrin for solid tumors being conducted at Dana-Farber Cancer Institute and Beth Israel Deaconess Medical Center has approved dosing for the eighth cohort. The dosing was been increased approximately 33 percent from the seventh cohort to 215 mg/m2. Enrollment for the eighth cohort is expected to commence shortly.

Cellceutix Comments on Positive FDA Advisory Vote for Dalbavancin and Tedizolid
Marketwire - Tue Apr 01, 7:04AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" is pleased to comment to its shareholders on yesterday's exciting regulatory developments and how it impacts Cellceutix's drug, Brilacidin.

Cellceutix Reports 20 Percent Enrollment Completed in Phase 2b Trial of Brilacidin as Short-Course Therapy for ABSSSI
Marketwire - Mon Mar 31, 8:25AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to provide shareholders an update on the status of the Company's clinical trial of its novel antibiotic Brilacidin as a treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI). One month into the study, the trial has completed enrollment of approximately 20 percent of the total patients scheduled in the protocol.

Cellceutix Initiates Clinical Trial of Prurisol as New Treatment for Psoriasis
Marketwire - Tue Mar 25, 5:01AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce the initiation of the Company's clinical trial of its oral, small molecule drug candidate Prurisol(TM) for the treatment of psoriasis. The Prurisol(TM) tablets have been delivered to the clinical site in Miami, Florida and screening of subjects can now begin with the first dosing expected in the coming days.

Cellceutix to Initiate Psoriasis Clinical Trial
Marketwire - Fri Mar 21, 5:00AM CDT
Cellceutix Corporation (OTCQB: CTIX) (the "Company" , a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, announces today that the U.S. Food and Drug Administration's ("FDA" 30-day waiting period pertaining to the Company's Investigational New Drug Application ("IND" for Prurisol(TM) has now passed. Cellceutix is moving towards the commencement of clinical trials of Prurisol(TM) as a new drug candidate for the treatment of psoriasis.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 114

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Lennar Faces Securities Fraud Lawsuit: Investor Insights

Updated Category News Views 108

Investors in Lennar: Navigating the Legal Storm Hold onto your hats, folks. Lennar Corporation (NYSE: LEN) is up against it with a brand-spanking-new securities fraud lawsuit helmed by Schall, Brown & Schwartz LLP (SBS). This isn't just a couple of investors grumbling over cocktails; it’s a full-blown class action that’s waving the legal banner under the Securities...

Continue Reading
HearUSA Expands Access with AI-Powered Hearing Aids

Updated Category News Views 92

AI Revolution in Hearing Care Look, the hearing aid industry isn't known for headlines that grab you by the throat, but HearUSA just tossed a proverbial grenade into the scene with Widex Allure AI RIC. This is more than a slight tweak in hearing tech—it's a game-changer. We're talking about on-demand AI noise management blended with Widex's renowned natural sound. It's...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 207

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading
Stephanie L. Beiermann Shines in HR Consulting Honors

Updated Category News Views 37

Celebrating a Star in Payroll Optimization Ah, the name Stephanie L. Beiermann’s been making the rounds lately, catching eyes with her lauded expertise in payroll optimization and human resources. This recognition doesn’t come out of thin air—no, it’s anchored on a solid foundation of over 25 years of cutting through the fluff to sharpen operational edges. We’re...

Continue Reading
Duolingo Faces Class Action: Key Investor Steps

Updated Category News Views 27

Navigating Turbulent Times with Duolingo Holy moly, the dumpster fire that is the Duolingo (NASDAQ:DUOL) legal saga just got hotter. If you snagged yourself some shares between May 2, 2025, and February 26, 2026, you'd better sit down and grab some antacids—because the nauseating roller coaster is far from over. Robbins LLP is rounding up the troops for a class action,...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 159

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 52

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 95

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
Vipshop Prepares for Q3 Financial Results Release

Updated Category News Views 93

Countdown to Vipshop's Third Quarter Results November 24th might just be another day on the calendar for some, but for those of us keeping tabs on the markets, it's a make-or-break moment for Vipshop Holdings Limited. The off-price retail titan from China, trailing under the ticker NYSE:VIPS, is gearing up to swing the doors wide open on its third-quarter financial...

Continue Reading

Top 5 Most Recently Viewed Articles

Trustmark Corporation Schedules Fourth Quarter Earnings Call

Updated Category News Views 204

Trustmark Corporation Plans Q4 Financial Results Announcement Trustmark Corporation (NASDAQGS:TRMK) is set to announce its fourth quarter financial results soon. The announcement will take place through a news release after the market closes. The company plays a vital role in the financial sector with its diverse offerings. Conference Call for Financial Discussion On the...

Continue Reading
VSee Health Experiences Significant Stock Surge After Approval

Updated Category News Views 271

VSee Health Inc. Stock Surges Over 45% Recently, VSee Health Inc. (NASDAQ: VSEE) experienced an impressive jump in its stock price, increasing by 45.28% to reach $1.54 during after-hours trading. This surge marks a notable uptick from its closing price of $1.06 earlier in the day, which represented a remarkable rise of 71.66% according to market data. Impact of Federal...

Continue Reading
Exciting Grand Opening for New Homes in Dacono, CO

Updated Category News Views 193

Exciting Grand Opening for New Homes in Dacono, CO Century Communities, Inc. (NYSE: CCS), a leading national homebuilder celebrated for its innovative approach to online home sales, is thrilled to unveil a Grand Opening event at Sweetgrass in Dacono. This event marks the debut of the community's stunning new model home, bringing an exciting opportunity for potential...

Continue Reading
Shakumoto Housei's Kickstarter: Artisan Neckties Unite People

Updated Category News Views 162

Shakumoto Housei's Journey to Craft Neckties with Heart In today's fast-paced world of fashion, Shakumoto Housei, a cherished small necktie manufacturer from Japan, is embarking on a unique adventure. This family-operated firm aims to connect with the global community through a heartfelt Kickstarter project. Rather than merely producing neckties, the initiative represents...

Continue Reading
Beko's Call for Sustainable Refrigeration in Food Security

Updated Category News Views 108

Refrigeration's Crucial Role in Global Food Security This year's World Food Day theme, 'Right to Foods for a Better Life and a Better Future', emphasizes the importance of worldwide access to food, highlighting the often-overlooked role of refrigeration. A recent report underscores that insufficient and unreliable refrigeration contributes significantly to food spoilage,...

Continue Reading